Can Local Drug Manufacturing Change the Cost Equation for HIV Prevention in South Africa?

South Africa is moving toward local production of Lenacapavir, a twice-yearly HIV prevention injection, following discussions with Gilead that opened a potential voluntary licence pathway. The rollout aims to address supply and affordability challenges for a country with more than 8 million people living with HIV, illustrating the wider challenge of translating medical breakthroughs into equitable public health outcomes.

South Africa is moving closer to manufacturing a local generic version of the HIV prevention drug Lenacapavir. Recently, Health Minister Dr Aaron Motsoaledi announced that discussions with Gilead, the drug's originator, have opened a pathway for a local manufacturer to obtain a voluntary licence to produce the medicine locally - a development that could expand access and slash costs for one of the countries hardest hit by HIV.

If local production succeeds, it could make Lenacapavir significantly more affordable than imported versions, potentially reshaping the HIV prevention landscape in South Africa.

South Africa has already begun rolling out Lenacapavir across public healthcare facilities. Donor-funded allocations are expected to reach hundreds of thousands of people as concerns remain that far larger numbers may be needed if the country is to make a meaningful impact on HIV transmission.

Why Lenacapavir Matters

Lenacapavir is among the most significant additions to HIV prevention strategies in decades. Unlike daily pre-exposure prophylaxis (PrEP), which relies on strict adherence, Lenacapavir's twice-yearly injection schedule simplifies prevention and reduces adherence barriers. Clinical trials demonstrated remarkable results: 100 percent efficacy among women in the study period and roughly 96 percent efficacy among men who have sex with men and transgender women. The World Health Organization has endorsed the drug as an additional prevention option for populations at elevated risk.

South Africa has an estimated 8.15 million people living with HIV, making access to effective prevention tools a central public health priority. For decades, the country has relied on large-scale procurement of antiretroviral therapies and donor-funded HIV prevention programs. Despite these efforts, new infection rates remain substantial, particularly among adolescents, young adults, and vulnerable communities. Local production of Lenacapavir aligns with broader public health priorities to expand access while reducing reliance on expensive imported medicines.

Lenacapavir forms part of a broader HIV prevention strategy and does not replace existing prevention and treatment measures. It could become an important addition to the country's prevention strategy if access can be scaled.

The Licensing Push Behind the Rollout

The issue is not only production, but affordability. If South Africa can secure local or lower-cost generic supply, the drug could become more accessible to people who need it most. Without broader access, a highly effective prevention tool risks remaining limited by price, supply or donor allocation.

The government is also working with international partners to accelerate access to lower-cost generic versions. Discussions involving the Clinton Health Access Initiative, UNITAID and Indian pharmaceutical company Dr Reddy's are focused on producing a generic version that could cost dramatically less than the current originator product.

A separate Gates Foundation-backed initiative is supporting Indian manufacturer Hetero to develop another affordable generic alternative. Regulatory review by South Africa's medicines authority, SAHPRA (South African Health Products Regulatory Authority), is underway, and Motsoaledi expressed confidence that generics could become available early next year. This approach reflects a growing global trend of combining local manufacturing, voluntary licensing, and international collaboration to expand access to essential medicines in low- and middle-income countries.

Gauteng Becomes an Early Test Case

South Africa has begun rolling out Lenacapavir through public healthcare facilities, with Gauteng among the first provinces implementing the programme. The primary beneficiaries of expanded Lenacapavir access include populations at high risk of HIV infection: adolescent girls and young women, adolescent boys and young men, sex workers, men who have sex with men, transgender individuals, people who inject drugs, and pregnant or breastfeeding women at high risk. Early rollout efforts in Gauteng province have identified 133 facilities, with enough stock to initiate treatment for more than 56,000 eligible individuals by March 2027. Quarterly deliveries are expected to sustain the program.

Government agencies are responsible for coordinating distribution and ensuring regulatory compliance. International organizations are investing resources to accelerate affordable access. Local manufacturers gain an opportunity to scale production and strengthen the domestic pharmaceutical sector. Donors, advocacy groups, and civil society remain critical in monitoring equity, supply sufficiency, and the integration of Lenacapavir into broader HIV prevention strategies.

Barriers Between Breakthrough and Access

Supply constraints, regulatory delays and licensing negotiations could all slow access. If generic versions are delayed, the country may remain dependent on donor-funded allocations and limited originator supply for longer than planned.

Lower prices matter because they can allow prevention programmes to expand beyond small priority cohorts and reach larger populations over time. There are also operational challenges. Public health facilities will need to identify eligible people, deliver injections on schedule, maintain follow-up systems and ensure that Lenacapavir is presented as part of a combination prevention package. The twice-yearly schedule may ease adherence, but it does not remove the need for existing testing, counselling, monitoring and linkage to other services.

The reliance on international partners and manufacturers for early generic production also introduces questions about production capacity, timelines and quality assurance. Local manufacturing could reduce some vulnerabilities, but it will not immediately solve every supply problem unless licensing, regulatory and procurement processes move together.

The Next Test: Approval, Supply and Scale

SAHPRA's regulatory review will shape how quickly generic versions can enter the market. The second is the licensing pathway with Gilead, including whether a South African manufacturer can secure terms that make local production commercially and publicly viable. The third is pricing, because the drug's reach will depend heavily on how far costs fall compared with the originator product.

Finally, early outcomes from the rollout, including adherence rates, uptake among priority populations, and potential reductions in new HIV infections, will provide data to evaluate the effectiveness of this strategic intervention.

South Africa's move toward local production of Lenacapavir, coupled with international collaboration on generics, represents a careful balance of innovation, access, and sustainability. While numerous operational and policy challenges remain, the initiative reflects a broader trend toward localized solutions for global health challenges, offering a potential model for other high-burden countries.